Köpeklerde xylazine uygulamasına bağlı gelişen bulantı ve kusmanın önlenmesinde antihistaminik kullanımı
Loading...
Date
2006-04-04
Authors
Börkü, M. Kazım
Özkanlar, Yunusemre
Hanedan, Başak
Ural, Kerem
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
Bir α2 adrenoreseptör agonisti olan xylazine uygulamasına bağlı olarak köpeklerde bradikardi, hipotansiyon, hipopnea, bulantı ve kusma gibi yan etkiler görülebilmektedir. Bu çalışma xylazine hydrochloride’e bağlı oluşan bulantı ve kusmanın önlenmesinde bir H1 reseptör antagonisti olan mepyramine maleate’ın etkinliğinin araştırılması amacıyla yapıldı. Çalışmada 30 köpek kullanıldı ve köpekler 10’arlı 3 gruba ayrıldı. Çalışmada antihistaminik uygulamasının yapıldığı an 0. dakika kabul edilerek, birinci guruptakilere 1 mg/kg, ikinci gruptakilere 2 mg/kg dozda intramuskuler (i.m.) mepyramine ve üçüncü gruptakilere ise eşit miktarda i.m. serum fizyolojik enjeksiyonu yapıldı. Bütün köpeklere bu enjeksiyonlardan 20 dakika sonra 2,2 mg/kg dozda i.m. xylazine enjekte edildi. Xylazine enjeksiyonundan sonra birinci ve ikinci gruptakilerden birer köpek kusarken üçüncü gruptakilerden sekiz köpek kustu. Üçüncü gruptakilerden dokuzunda bulantı gözlenirken, birinci grupta 2 ve ikinci grupta 3 köpekte bulantı saptandı. Birinci ve ikinci gruplarda mepyramine uygulamasından sonraki 40., 60. ve 80. dakikalarda (xylazine uygulamasından sonraki 20., 40. ve 60. dakikalar) pulzasyon ve respirasyon önemli (P<0,001) oranda düşerken, beden ısılarındaki düşüşün istatistiksel önemi yoktu. Sonuç olarak, köpeklerde mepyramine’in xylazine’e bağlı bulantı ve kusmanın önlenmesinde etkili olduğu, diğer parametrelerde istatistik önemi bulunan bir değişikliğin olmadığı belirlendi.
Xylazine, α2-adrenoreceptor agonist, may adversely cause bradycardia, hypotension, hypopnea, nausea and vomiting in dogs. This study was performed to investigate the effect of mepyramine maleate, an antihistaminic, on the prevention of vomiting and nausea after administration of xylazine hydrochloride. Thirty dogs were used in this study and they were divided into three groups of ten dogs each. After having assigned the point of antihistaminic administration as 0 minute in the study, mepyramine was injected intramuscularly (i.m.) 1 mg/kg for group I and 2 mg/kg for group II and equivalent volume of physiologic serum was injected i.m. for group III. Xylazine, 2.2 mg/kg i.m., was injected to all dogs 20 minutes after mepyramine administration. While one dog vomited from group I and group II, eight dogs vomited in group III after xylazine administration. Nausea was detected in two dogs of group I, in three of group II and in nine of group III. Pulsation and respiration decreased significantly (P<0.001), and body temperatures declined insignificantly at 40th, 60th and 80th minutes relative to mepyramine administration (20th, 40th and 60th minutes relative to xylazine administration) in group I and group II. In conclusion, mepyramine is effective to prevent nausea and vomiting induced by xylazine in dogs and any changes were not found over other parameters statistically significant.
Xylazine, α2-adrenoreceptor agonist, may adversely cause bradycardia, hypotension, hypopnea, nausea and vomiting in dogs. This study was performed to investigate the effect of mepyramine maleate, an antihistaminic, on the prevention of vomiting and nausea after administration of xylazine hydrochloride. Thirty dogs were used in this study and they were divided into three groups of ten dogs each. After having assigned the point of antihistaminic administration as 0 minute in the study, mepyramine was injected intramuscularly (i.m.) 1 mg/kg for group I and 2 mg/kg for group II and equivalent volume of physiologic serum was injected i.m. for group III. Xylazine, 2.2 mg/kg i.m., was injected to all dogs 20 minutes after mepyramine administration. While one dog vomited from group I and group II, eight dogs vomited in group III after xylazine administration. Nausea was detected in two dogs of group I, in three of group II and in nine of group III. Pulsation and respiration decreased significantly (P<0.001), and body temperatures declined insignificantly at 40th, 60th and 80th minutes relative to mepyramine administration (20th, 40th and 60th minutes relative to xylazine administration) in group I and group II. In conclusion, mepyramine is effective to prevent nausea and vomiting induced by xylazine in dogs and any changes were not found over other parameters statistically significant.
Description
Keywords
Köpek, Dog, Xylazine, Mepyramine maleate, Kusma, Antihistaminik, Vomiting, Antihistaminic
Citation
Börkü, M. K. vd. (2006). "Köpeklerde xylazine uygulamasına bağlı gelişen bulantı ve kusmanın önlenmesinde antihistaminik kullanımı". Uludağ Üniversitesi Veteriner Fakültesi Dergisi, 24(1-2-3-4), 99-104.